4.3 Article

Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling

Journal

ONCOTARGET
Volume 7, Issue 50, Pages 83308-83318

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.13088

Keywords

breast cancer; metastasis; AXL; signal transduction; kinase inhibitor

Funding

  1. Creative Fusion Research Program through the Creative Allied Project - National Research Council of Science and Technology [CAP-12-1-KIST]
  2. Bio & Medical Technology Program of the NRF - Korean government, MSIP [2014M3A9D9033717]
  3. Medical Cluster R&D Support Project through Daegu Gyeongbuk Medical Innovation Foundation - Ministry of Health & Welfare, the Republic of Korea [HT13C0006]
  4. Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [A111345]
  5. Bio & Medical Technology Development Program of the NRF - Korean government, MSIP [2014M3A9D9905123]
  6. National Research Foundation of Korea [2014M3A9D9033717] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Breast cancer is the most common malignant disease occurring in women and represents a substantial proportion of the global cancer burden. In these patients, metastasis but not the primary tumor is the main cause of breast cancer-related deaths. Here, we report the novel finding that DN10764 (AZD7762, a selective inhibitor of checkpoint kinases 1 and 2) can suppress breast cancer metastasis. In breast cancer cells, DN10764 inhibited cell proliferation and GAS6-mediated AXL signaling, consequently resulting in suppressed migration and invasion. In addition, DN10764 induced caspase 3/7-mediated apoptosis in breast cancer cells and inhibited tube formation of human umbilical vein endothelial cells. Finally, DN10764 significantly suppressed the tumor growth and metastasis of breast cancer cells in in vivo metastasis models. Taken together, these data suggest that therapeutic strategies targeting AXL in combination with systemic therapies could improve responses to anti-cancer therapies and reduce breast cancer recurrence and metastases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available